Key Takeaways Regeneron will report Q4 results on Jan. 30, with focus on profits from Dupixent and Eylea HD sales.Eylea sales declined due to competition, but strong uptake of Eylea HD may lift total franchise revenues.Dupixent demand across multiple indications likely drove solid profit growth, helping offset Eylea decline.Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, Inc. (REGN) reports fourth-quarter 2025 results on Jan. 30, ...